Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No End In Sight: Pharma Companies Continue To Face Government Probes

You may also be interested in...



Amarin Aims Vascepa For The Sweet Spot Of Dyslipidemia

FDA leaves door open to modify label of Amarin’s omega-3 fatty acid therapy Vascepa prior to approval in a healthier population, says company CEO. Per the current label, triglycerides are lowered significantly with no increase in LDL cholesterol, a potential differentiating point from Pronova/Glaxo’s blockbuster EPA/DHA therapy Lovaza.

Senators Seek “Fresh” Ideas To Fight Health Fraud From Stakeholders

An open letter to the “health care community” from a bipartisan group of senators on the Finance Committee asks for white papers offering suggestions on the best ways to combat “the multi-billion dollar problem” of waste, fraud and abuse in Medicare and Medicaid.

Rx Fraud Cases: Beat Goes On As Whistleblowers Pursue Lesser Allegations

“There are enough layoffs out there that there is this walking group of disaffected people who are continuing to file qui tams, whether those are valid or not,” Boston Assistant U.S. Attorney Susan Winkler says. A Pfizer attorney suggests proactive steps to protect corporate leaders from prosecution.

Related Content

Topics

UsernamePublicRestriction

Register

PS053695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel